Abstract: The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD 154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells.

Abstract: The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.

Abstract: The present invention relates to isolated Visceral leishmaniasis (VL) antigens that are useful in therapeutic and vaccine compositions for stimulating a VL specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active VL in an individual. Combinations of antibodies raised against these antigens are especially useful in detection of VL infections. Accordingly, the present invention includes polypeptide molecules, nucleic acid molecules, vaccine compositions, diagnostic assays, and methods of diagnosis and monitoring treatment related to these VL antigens.

Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). Also disclosed are a phage-display screening method for identifying such therapeutic peptides, and peptides that hind specifically to BTICs or HIGCs.

Abstract: The invention provides chemically and physically stable topical formulations of pexiganan, and methods of preparing the same.

Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.

Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.

Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.

Abstract: Lipopeptide compounds comprising a peptide having 2 to 100 amino acid residues, and having a lipophilic group attached to at least one terminus of the peptide or to at least one amino acid residue of the peptide, and salts and uses thereof. The lipophilic group may be attached to the N-terminus, C-terminus or both termini of the peptide. The lipophilic group may be attached to at least one interal amino acid residue (i.e., an amino acid residue that is not the N-terminus or the C-terminus amino acid residue of the peptide). The lipophilic group may be attached to either termini or both and at least one internal amino acid residue.

Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.

Abstract: The invention relates to polypeptides, comprising repeats of peptides derived from apolipoproteins, which exhibit antibacterial activity and to nucleic acids encoding the same. The invention further provides the use of such polypeptides, derivatives, analogues or nucleic acids as medicaments, and also their use in methods of preventing or treating bacterial infection or objects and surfaces. The invention further extends to objects, such as contact lenses, coated with the polypeptides.

Abstract: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.

Abstract: The present invention is directed to methods of detecting viable epithelial cells in a sample. The method includes isolating the sample comprising cells from a patient and culturing the cells for a time sufficient for an epithelial cell-specific marker to be released from the cells. The marker includes a substantially full-length cytokeratin. The method further includes detecting the released marker. Detection of the marker indicates the presence of disseminated epithelial cells. Methods are also directed to identifying disseminated epithelial tumor cells.

Abstract: The present invention relates to antimicrobial peptides, to their use as antimicrobial agents and to their use in the treatment of (infectious) diseases, in particular infectious diseases caused by Gram-positive bacteria, Gram-negative bacteria, yeast or fungi. The present invention further relates to pharmaceutical compositions and kits comprising the antimicrobial peptides and to a method of lysing bacterial, yeast or fungal cells. The antimicrobial peptides consist of one of the following general formula: Wherein X is a hydrophobic amino acid, Y is a cationic amino acid, Z is an amino acid having a free thiol or thioether group, n is 2-4 and m is 0 or 1.

Abstract: The invention provides an isolated peptide comprising a crotonylation site, a Kcr-specific affinity reagent that specifically binds to the peptide, and a method for detecting protein crotonylation in a sample using the reagent.

Abstract: The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-GL and Bcl-GS. The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.

Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.

Abstract: A method of solid phase selection of peptide ligands for target proteins is presented. 15-20mers or greater are addressed in a microarray, and the target protein and optional competitor bound thereto and binding compared. A specific signal for the target protein indicates that a peptide has strong affinity for the target. Ligands can be coupled to solid supports and used for affinity purification of the target proteins as well as detection and modulation of target proteins. Specific peptide ligands for immuno-purifying norovirus.

Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.

Abstract: The present invention presents new insights in the mechanism of action of the estrogen receptor alpha in breast cancer cells and provides means and tools for modulating said mechanisms of action, thereby influencing the proliferation of estrogen-positive cells such as cancer cells.

Abstract: Described herein are compounds and methods useful in the detection of, e.g., Zn2+, in vitro and in vivo. The compounds include amino acids and peptides functionalized with a moiety that binds, e.g., Zn2+. The peptides may be further functionalized with a detectable moiety. The peptides may also comprise amino acid sequences known to localize extracellularly or in specific areas within a cell.

Abstract: The present invention provides methods and compositions for treating inflammation and inflammatory disorders in a subject, by administering an effective amount of KSHV-Orf63 and/or active peptides and/or fragments thereof.

Abstract: Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.

Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.

Abstract: The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.

Abstract: The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method.

Abstract: The invention relates to a newly identified avian rotavirus D VP6 nucleotide sequence and uses thereof.

Abstract: There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.

Abstract: Provided herein are compositions and methods for the treatment of cancers. The compositions comprise at least one VEGF peptide mimic, HER-2 epitope, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. The peptides and epitopes may be linear, cyclized, retro-inverso, or a combination of such forms. Also provided herein are antibodies raised to VEGF peptide mimics, HER-2 epitopes, immunogenic VEGF peptides, and HER-2 immunogenic epitopes.

Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple ?c-cytokine family members.

Abstract: Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to RSP3 or Ash2L and that bind to Dpy-30.

Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

Abstract: An object of the invention is to provide a peptide based on a sequence of an amyloid ? peptide that may allow for induction of enhanced immune response and is safe and efficacious for prophylaxis and treatment of Alzheimer disease. An amyloid ? peptide or a portion thereof with addition or insertion of cysteine or a cysteine analogue, and a method for enhancing immune response to amyloid ? using said peptide, a medicament for prophylaxis and treatment of Alzheimer disease using said amyloid ? peptide that induces an enhanced immune response, and a DNA vaccine comprising a gene coding for an amyloid ? peptide or a sequence derived from an amyloid ? peptide with addition or insertion of cysteine or a cysteine analogue, as expected to be similarly efficacious.

Abstract: The present invention provides a marker capable of detecting insulin resistance and diabetes in a collected blood sample, a method for analyzing said marker, a method for screening a substance improving insulin resistance, and improving or suppressing diabetes. A blood insulin resistance marker and a blood diabetes marker, which comprises a polypeptide comprising at least 15 continuous amino acids in an amino acid sequence constituting progranulin. A method for analyzing a blood marker, which comprises the steps of: measuring a concentration of an insulin resistance marker or a diabetes marker in a collected blood sample; and comparing the measured concentration with a normal blood concentration of the marker.

Abstract: The invention provides novel peptides and constructs. In addition the invention provides methods for carrying compounds across the cell membrane, for antagonizing or destroying X-protein of HBV, treatment and/or management of HBV infection, treatment and/or prevention of HCC, and degradation of a target protein.

Abstract: Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.

Abstract: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.

Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors.

Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.

Abstract: The present invention relates to human papillomavirus E7 antigen compounds and compositions for treating human papillomavirus infection and associated conditions. The invention provides, in part, polypeptide and nucleic acid molecules including sequences substantially identical to the sequences of two or more human papillomavirus (HPV) E7 antigens, where the E7 antigens are selected from at least two different HPV strains, and methods of using the same.

Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CX-CR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow trans-plantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine.

Abstract: The present invention provides compositions and methods for killing or suppressing growth of Gram-negative bacteria that infect, infest or cause disease in plants, including pathogenic, saprophytic and opportunistic microbes that cause disease in plants and food borne illness in people or in animal feed.

Abstract: This invention relates to the detection and analysis by mass spec of nascent proteins, and in particular truncated proteins, translated within cellular or cell-free translation systems. N-terminal and C-terminal epitopes introduced into these nascent proteins permit rapid and efficient isolation, as well as mass difference.

Abstract: The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.

Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors.

Abstract: Use of flagellins from the genus Marinobacter as vaccine adjuvants. This invention is based on the use of two recombinant flagellins, F and FR, from the species Marinobacter algicola (DG893T strain), as vaccine adjuvants capable of developing a specific immune response, against peptides or proteins fused to said flagellins, or administered unfused jointly with the flagellins. This invention also describes new combined vaccination strategies, based on the two Marinobacter algicola flagellins and the Salmonella typhimurium flagellin.

Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.

Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

Abstract: Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8+ T cell response or an anti-DV CD4+ T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.